

3. An ophthalmic solution according to claim 1, further comprising one or more buffers.

21
C
4. An ophthalmic solution according to claim 1, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of ^{said} poloxamer ~~407~~.

8. Use according to claim 6, wherein said ophthalmic solution contains sodium hyaluronate as viscosity enhancing agent.

Attached hereto is page 3 that presents a marked up version of the changes made to claims 3, 4 and 8 by this preliminary amendment. Page 3 is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

By: Clifford W. Browning
Clifford W. Browning
Reg. No. 32,201
Woodard, Emhardt, Naughton,
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, Indiana 46204-5137
(317) 634-3456

#143192

THE **NEW** **YORK** **PUBLIC** **LIBRARY**

4. (Amended) An ophthalmic solution according to [any one of the preceding claims] claim 1, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer 407.

-3-

A